Kenise Morris, PhD, MEng, BCMAS

Field Medical & Scientific Strategy
Fractional Scientific & Clinical Liaison Services
kenise.science@gmail.com
linkedin.com/in/kenise-morris
202-930-5491
Available for Travel
I help early-stage biotech and life science companies translate their science into clinical credibility, meaningful key opinion leader (KOL) relationships, and investor-ready narratives — without the overhead of a full-time hire.
Book a Discovery Call
The problem I solve
Pre-seed and seed-stage biotechs are building novel science — but rarely have someone who can speak it fluently to clinicians and key opinion leaders, prepare it for investor diligence, and flag the regulatory considerations that protect the company long-term. The companies that reach their next milestone with clinical momentum are the ones that lay this groundwork early. That gap is where I operate.
Your science is compelling but your investor pitch isn't landing with scientific or clinical stakeholders
You know you need relationships with leading clinicians and clinical experts but don't know who to approach, how to structure the conversation, or what to ask
Your team is making scientific claims in pitch decks or on your website that haven't been validated against regulatory expectations
You're preparing for your next raise and need peer-reviewed evidence, congress presence, or clinical validation to strengthen your scientific narrative
You haven't mapped the clinical landscape — who the key clinicians are, what they need, and how your platform fits into their practice — critical groundwork that's easy to overlook at the early stages
You're a technical founder wearing too many hats — and even with AI tools, scientific outreach, clinical engagement, and evidence strategy are falling through the cracks
Scientific Narrative & Evidence Communication
Translate complex platform science into clinical language for investors, KOLs, and HCPs — including pitch deck audits and scientific white papers.
Medical Writing & Publication Support
Support manuscript preparation, abstract submissions, and publication planning to help early-stage companies build their evidence base and establish scientific credibility.
KOL Identification & Mapping
Identify and vet key opinion leaders for your therapeutic or diagnostic area. Build a prioritized engagement list with scientific rationale and recommended outreach approach.
Peer-to-Peer Scientific Exchange
Serve as the scientific face of your company in meetings with KOLs, clinical investigators, and HCPs — gathering insights, building relationships, and supporting trial or adoption goals.
Regulatory Intelligence & Considerations
Provide early regulatory intelligence to help founders understand applicable pathways, evidence requirements, and scientific claim considerations — building regulatory awareness before it becomes a bottleneck.
Medical Affairs & Clinical Advisory
Identify evidence gaps, support clinical positioning, study design considerations, and congress intelligence — laying the scientific groundwork before a full medical affairs hire makes sense.
Attend conferences and meetings on your company's behalf — conducting competitive intelligence, engaging KOLs and clinical investigators, sharing and communicating data, and representing your platform to the broader scientific community. Findings are synthesized into actionable post-congress briefings for your leadership team.
I
Discovery Call
A conversation to understand your science, current stage, and where scientific or clinical strategy support is needed.
II
Scope & Proposal
A defined scope, timeline, and fee structure — project-based, retainer, or per-engagement — so you know exactly what to expect before committing.
III
Embedded Work
I immerse myself in your platform, data, and the surrounding literature, then execute — drafting, KOL mapping and outreach, or representing you at a conference or meeting.
IV
Deliver & Advise
You receive the deliverable, a debrief on findings and field insights, strategic implications, and recommended next steps — with ongoing check-ins for retainer engagements.
01 Led an IRB-approved translational clinical study within a GCP-regulated trial environment validating a novel liquid biopsy platform for CTC capture in advanced cancer patients — responsibilities spanned IRB support, sample logistics, protocol adherence, data reporting, and coordination with a clinical collaborator.
02 5 peer-reviewed publications in oncology and thrombosis, with research experience spanning cellular diagnostics and therapeutics, platelet–cancer interactions, and liquid biopsy platforms; 8+ national conference presentations; contributed to successful grant submissions through technical writing and preliminary data generation.
03 Board Certified Medical Affairs Specialist (BCMAS); M.Eng. in Regulatory Biomedical Engineering; NIH IPPCR-certified in clinical research principles and practice.
04 Invited peer reviewer for 6 oncology-hematology journals; Adjunct Professor of Biomedical Engineering with demonstrated scientific communication across diverse audiences.
Biomedical Engineering Life Sciences Oncology Liquid Biopsy & Diagnostics Circulating Tumor Cells (CTC) ctDNA / MRD Platelet–Cancer Interactions Hematology Tumor Microenvironment & Metastasis Cellular Therapeutics
PhD · Biomedical Engineering — Cellular Diagnostics & Therapeutics (GWU) Board Certified Medical Affairs Specialist (BCMAS) M.Eng · Regulatory Biomedical Engineering NIH Introduction to Principles & Practice of Clinical Research (IPPCR) Member · Medical Science Liaison Society (MSLS) Member · Women in Bio
Pre-seed & seed life science startups Series A/B raising scientific credibility Companies preparing for first clinical study or KOL engagement Diagnostic companies & liquid biopsy platforms CTC / ctDNA platforms AI-powered diagnostic platforms Multi-cancer early detection (MCED) Cell-Based Therapeutics Academic spinouts entering commercial translation International founders building US presence & strategy